OptiCor, a cutting-edge Clinical Decision Support Software, leads the way in cardiovascular care by seamlessly incorporating the latest 2023 ACC/AHA Guideline for Atrial Fibrillation. With a validated risk prediction algorithm, OptiCor empowers healthcare professionals with individualized stroke risk assessments, navigating away from the conventional CHA2DS2-VASc scoring system. This paradigm shift aligns perfectly with the guideline's emphasis on personalized therapy decisions, resulting in a significant reduction in mortality, stroke, and bleeding compared to standard care. The user-friendly interface and EHR integration of the enhanced version position OptiCor as the exclusive solution for implementing the new guideline, reinforcing its commitment to shaping the future of cardiovascular care through evidence-based precision and innovation.

tenacio transforms cardiovascular care by using individual risk prediction and curated treatment recommendations which help health care providers to provide efficient care and optimal treatments for patients, resulting in better outcomes and lower cost.

OptiCor is the only Clinical Decision Support which incorporates the 2023 ACC/AHA AF Guideline because it provides precise treatment decisions based on individual stroke risk prediction.

Its focus is on proven outcome improvements and a superior user experience, making it easier and faster for HCPs to identify the optimal treatment for a patient. 

• Only CDS which supports the new 2023 ACC/AHA AF treatment paradigm
• Proven outcome benefits and cost savings
• Superior user experience
• FDA reviewed, proprietary and validated risk prediction algorithm